Compass Therapeutics, Inc. Common Stock (CMPX) is a publicly traded Healthcare sector company. As of May 21, 2026, CMPX trades at $1.85 with a market cap of $329.56M and a P/E ratio of -4.46. CMPX moved +3.87% today. Year to date, CMPX is -62.12%; over the trailing twelve months it is -10.00%. Its 52-week range spans $1.27 to $6.88. Analyst consensus is strong buy with an average price target of $10.11. Rallies surfaces CMPX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Compass Therapeutics Phase 2/3 Tovecimig Achieves 17.1% ORR, Holds $195M Cash: Compass Therapeutics reported Phase 2/3 tovecimig plus paclitaxel in biliary tract achieved a 17.1% response rate versus 5.3% extending PFS to 4.7 versus 2.6 months (HR 0.44, p<0.0001). The company has $195 million cash, gained Orphan Drug Designation for tovecimig and plans a BLA this year while advancing two Phase 1 bispecific antibody candidates.
| Metric | Value |
|---|---|
| Price | $1.85 |
| Market Cap | $329.56M |
| P/E Ratio | -4.46 |
| EPS | $-0.42 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.88 |
| 52-Week Low | $1.27 |
| Volume | 3.40M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-66.49M |
| Gross Margin | 0.00% |
12 analysts cover CMPX: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.11.